Akari Therapeutics

42 articles with Akari Therapeutics

• Akari Therapeutics Reports First Quarter 2019 Financial Results And Highlights Recent Clinical Progress

  5/29/2019

  Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement and/or leukotriene systems are implicated, today announced its financial results for the first quarter ended March 31, 2019 and recent clinical progress.

• Akari Therapeutics Announces Expanded Ophthalmology Program Based on Positive Emerging Data on LTB4-C5 Dual Action in Surface and Back of the Eye Diseases

  4/26/2019

  Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announced encouraging new data in both the surface and the back of the eye.

• Akari Therapeutics Announces Positive Initial Phase II Clinical Data in Orphan Skin Disease Bullous Pemphigoid

  4/23/2019

  Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announces positive initial Phase II clinical data from the first three of bullous pemphigoid (BP) patients in an ongoing clinical trial.

• Akari Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights

  4/23/2019

  Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement and/or leukotriene systems are implicated, today announced its financial results for the fourth quarter and full year ended December 31, 2018.

• Akari Therapeutics to Provide Update on its Eye Disease Program During Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

  3/28/2019

  Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announces that it will provide an update on its eye diseases program during the 2019 Annual Meeting of The Association for Research in Vision and Ophthalmology (ARVO) being held April 28-May 2, 2019 in Vancouver, B.C.

• Akari Therapeutics Announces New Data Highlighting Differentiation of Drug Candidate Coversin

  11/30/2018

  Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced recent developments and supporting data which underscore the differentiation of Coversin.

• Akari Announces Coversin Data to be Presented at 2018 Complement-Based Drug Development Summit

  11/15/2018

  Highlights potential role of both complement and leukotriene pathways in a therapeutic mouse model of rheumatoid arthritis (RA)

• Akari Announces Third Quarter 2018 Financial Results and Business Highlights

  11/15/2018

  Four ongoing clinical trial programs

• Akari Therapeutics Announces New Clinical Data in Post-Transplant Thrombotic Microangiopathies

  9/30/2018

  Data Supports Akari’s Ongoing Clinical Expansion into a Range of Orphan Autoinflammatory Diseases That Are Either Mediated by Complement C5 or Have Synchronous C5 and Leukotriene B4 (LTB4) Activity

• Akari Announces Second Quarter 2018 Financial Results and Business Highlights

  9/27/2018

  Announced Securities Purchase Agreement For Up To $20 Million with Aspire Capital Fund, LLC

• Akari Therapeutics Enters into a Securities Purchase Agreement for up to $20 Million with Aspire Capital Fund, LLC

  9/27/2018

  Akari Therapeutics, Plc today announces that it has entered into a Securities Purchase Agreement (the “Agreement”) of up to $20 million with Aspire Capital Fund, LLC

• Akari Therapeutics Announces New Preclinical Rheumatoid Arthritis Data and New Clinical Data in Patients with Bullous Pemphigoid

  9/13/2018

  Akari Therapeutics Announces New Preclinical Rheumatoid Arthritis Data and New Clinical Data in Patients with Bullous Pemphigoid, Highlighting Potential Advantages of Coversin’s Bifunctional Activity Inhibiting Both the Complement and Leukotriene Inflammatory Pathways

• Akari Therapeutics Announces New Data Highlighting Potential Advantages of Coversin’s Bifunctional Activity Inhibiting Both the Complement and Leukotriene Inflammatory Pathways

  9/13/2018

  Akari Therapeutics Announces New Preclinical Rheumatoid Arthritis Data and New Clinical Data in Patients with Bullous Pemphigoid, Highlighting Potential Advantages of Coversin’s Bifunctional Activity Inhibiting Both the Complement and Leukotriene Inflammatory Pathways

• 

  Akari CEO Abruptly Resigns Following Abuse of Corporate Credit Card

  5/11/2018

  For the second time in less than one year, Akari Therapeutics is without a chief executive officer. David Horn Solomon abruptly resigned after being caught using the company credit card for personal purposes.
• 

  Foresite Capital Launches New Venture Capital Fund Worth $668 Million

  5/3/2018

  Venture capital firm Foresite Capital, located in San Francisco, is launching a new fund, its fourth and largest, worth $668 million.

• Akari Therapeutics Announces Completion of Phase II COBALT Trial of Coversin in Patients with PNH and Further Progress of Clinical Trials

  2/6/2018

  The final three patients enrolled in the eight patient 90-day open-label Phase II single-arm COBALT clinical trial for patients with PNH who have never received a complement blocking therapy, have now completed the trial.

• Akari Therapeutics Strengthens Board With Two Senior Industry Appointments

  1/23/2018

  The company appointed Michael Grissinger and Dr. Peter Feldschreiber to the Company’s Board of Directors with immediate effect.

• Akari Therapeutics Announces Pricing of Public Offering of American Depositary Shares

  10/18/2017

  Akari granted the underwriters a 30-day option to purchase up to an additional 522,000 ADSs at the public offering price.

• Akari Announces Further Clinical Progress

  10/11/2017

• Akari: What's Next For This 'Busted IPO'?

  10/4/2017